  Chemistry42 is a software platform for de novo small molecule design that
integrates Artificial Intelligence (AI) techniques with computational and
medicinal chemistry methods. Chemistry42 is unique in its ability to generate
novel molecular structures with predefined properties validated through in
vitro and in vivo studies. Chemistry42 is a core component of Insilico Medicine
Pharma.ai drug discovery suite that also includes target discovery and
multi-omics data analysis (PandaOmics) and clinical trial outcomes predictions
(InClinico).
